Skip to main content

Advertisement

SpringerLink
Log in

Strategies and methodologies for identifying molecular targets in sarcomas and other tumors

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Sarcomas are a heterogeneous group of tumors that respond poorly to conventional cytotoxic chemotherapy. Sarcomas possess specific molecular characteristics that exist because of unique somatic mutations, vital growth factor or growth factor receptor overexpression, or are critically dependent on host pathways. Currently these tumors are classified on the basis of their tissue of origin and histologic appearance. Gene expression and proteomic analysis of sarcomas may enable reclassification of these tumors and help predict their biologic behavior and devise common therapeutic strategies within a class. It may not be long before cDNA/protein expression profiling and karyotyping complement the current standard pathological evaluation of a newly diagnosed sarcoma, thereby helping the clinician pick targeted agent(s) relevant to the expression profile. The spectacular success of imatinib in patients with gastrointestinal stromal tumor demonstrates how molecular targeting can fulfill the promise of low toxicity and high response rates. Finding new targets, and learning how to use the current generation of targeting drugs in sarcoma, are urgent challenges. Therapeutic clinical trials with a host of new molecular-targeting agents are underway that will drive new paradigms in sarcoma therapeutics. Patients with refractory disease who currently have no viable therapeutic options may have options that open up with the advent of newer targeted approaches, converting their disease from an acute short-lived one to a chronic process with preservation of quality of life while receiving therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Jemal A, Murray T, Ward E, et al.: Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10–30.

    Article  PubMed  Google Scholar 

  2. Maki RG: Role of chemotherapy in patients with soft tissue sarcomas. Expert Rev Anticancer Ther 2004, 4:229–236.

    Article  PubMed  CAS  Google Scholar 

  3. Brennan MF, Alektiar KM, Maki RG:Soft tissue sarcoma. In Cancer:Principles and Practice of Oncology, edn 6. Edited by Vincent T, DeVita J, Hellman S, Rosenberg SA. Philadelphia:Lippincott Williams & Wilkins; 2001:1845–1847.

    Google Scholar 

  4. Adjuvant chemotherapy for localised resectable softtissue sarcoma of adults:meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997, 350:1647-1654.

  5. Brennan MF, Alektiar KM, Maki RG:Soft tissue sarcoma:Table 39. 1–15. In Cancer:Principles and Practice of Oncology, edn 6. Edited by Vincent T, DeVita J, Hellman S, Rosenberg SA. Philadelphia:Lippincott Williams & Wilkins; 2001:1880.

    Google Scholar 

  6. Helman LJ, Meltzer P: Mechanisms of sarcoma development. Nat Rev Cancer 2003, 3:685–694. This is an excellent review of the molecular biology of sarcomas.

    Article  PubMed  CAS  Google Scholar 

  7. Demetri GD, von Mehren M, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472–480.

    Article  PubMed  CAS  Google Scholar 

  8. Heinrich MC, Corless CL, Demetri GD, et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003, 21:4342–4349.

    Article  PubMed  CAS  Google Scholar 

  9. Weiner LM, Adams GP, Mehren MV:Therapeutic monoclonal antibodies:general principles. In Cancer:Principles and Practice of Oncology, edn 6. Edited by Vincent T, DeVita J, Hellman S, Rosenberg SA. Philadelphia:Lippincott Williams & Wilkins; 2001:495–508.

    Google Scholar 

  10. Neidle S, Thurston DE: Chemical approaches to the discovery and development of cancer therapies. Nat Rev Cancer 2005, 5:285–296.

    Article  PubMed  CAS  Google Scholar 

  11. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991, 253:49–53.

    Article  PubMed  CAS  Google Scholar 

  12. Vassilev LT, Vu BT, Graves B, et al.: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844–848.

    Article  PubMed  CAS  Google Scholar 

  13. Gschwind A, Fischer OM, Ullrich A: The discovery of receptor tyrosine kinases:targets for cancer therapy. Nat Rev Cancer 2004, 4:361–370.

    Article  PubMed  CAS  Google Scholar 

  14. Reynolds NA, Wagstaff AJ: Cetuximab in the treatment of metastatic colorectal cancer. Drugs 2004, 64:109–118; discussion 119–121.

    Article  PubMed  CAS  Google Scholar 

  15. Shin DM, Donato NJ, Perez-Soler R, et al.: Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001, 7:1204–1213.

    PubMed  CAS  Google Scholar 

  16. Herbst RS, Hong WK: IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Semin Oncol 2002, 29:18–30.

    PubMed  CAS  Google Scholar 

  17. Sato O, Wada T, Kawai A, et al.: Expression of epidermal growth factor receptor ERBB2 and KIT in adult soft tissue sarcomas:a clinicopathologic study of 281 cases. Cancer 2005, 103:1881–1890.

    Article  PubMed  CAS  Google Scholar 

  18. Scartozzi M, Bearzi I, Berardi R, et al.: Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites:implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 2004, 22:4772–4778.

    Article  PubMed  CAS  Google Scholar 

  19. Hynes NE, Lane HA: ERBB receptors and cancer:the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5:341–354. A review of ERBB receptor family as potential targets for therapy.

    Article  PubMed  CAS  Google Scholar 

  20. Kim T: Technology evaluation:matuzumab, Merck KGaA. Curr Opin Mol Ther 2004, 6:96–103.

    PubMed  CAS  Google Scholar 

  21. Arteaga CL, Johnson DH: Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol 2001, 13:491–498.

    Article  PubMed  CAS  Google Scholar 

  22. Kerbel R, Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002, 2:727–739. An excellent review of anti-angiogenic strategies in solid tumors.

    Article  PubMed  CAS  Google Scholar 

  23. Vergote IB, Humblet Y, Cutsem EV, et al.:A multicenter phase II trial of gefitinib 500 mg/day in 193 patients with advanced epidermal growth factor receptor-positive solid tumors who had failed previous chemotherapy:interim data. Paper presented at the 2005 ASCO Annual Meeting. Orlando, FL; May 13–17, 2005.

  24. US National Institutes of Health:http://www.clinicaltrials. gov. Accessed September 6, 2005.

  25. Sliwkowski MX, Lofgren JA, Lewis GD, et al.: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999, 26:60–70.

    PubMed  CAS  Google Scholar 

  26. Pegram M, Hsu S, Lewis G, et al.: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999, 18:2241–2251.

    Article  PubMed  CAS  Google Scholar 

  27. Molina MA, Codony-Servat J, Albanell J, et al.: Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001, 61:4744–4749.

    PubMed  CAS  Google Scholar 

  28. Vogel CL, Cobleigh MA, Tripathy D, et al.: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719–726.

    Article  PubMed  CAS  Google Scholar 

  29. Slamon DJ, Leyland-Jones B, Shak S, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783–792.

    Article  PubMed  CAS  Google Scholar 

  30. Mehta TS, Hsiang D, Kong K:Phase II study of neoadjuvant biweekly doxorubicin and cyclophosphamide (AC) with GM-CSF followed by weekly paclitaxel, carboplatin +/- trastuzumab (TC +/- H) in the treatment of breast cancer (BC) [abstract No. 826]. Paper presented at the 2005 ASCO Annual Meeting. Orlando, FL; May 13–17, 2005.

  31. Mohsin SK, Weiss HL, Gutierrez MC, et al.: Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 2005, 23:2460–2468.

    Article  PubMed  CAS  Google Scholar 

  32. Thomas DG, Giordano TJ, Sanders D, et al.: Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer 2005, 103:830–838.

    Article  PubMed  CAS  Google Scholar 

  33. Gorlick R, Huvos AG, Heller G, et al.: Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999, 17:2781–2788.

    PubMed  CAS  Google Scholar 

  34. Zhou Z, Jia SF, Hung MC, Kleinerman ES: E1A sensitizes HER2/neu-overexpressing Ewing’s sarcoma cells to topoisomerase II-targeting anticancer drugs. Cancer Res 2001, 61:3394–3398.

    PubMed  CAS  Google Scholar 

  35. Thomas DG, Giordano TJ, Sanders D, et al.: Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing’s sarcoma. Clin Cancer Res 2002, 8:788–793.

    PubMed  CAS  Google Scholar 

  36. Ye D, Maitra A, Timmons CF, et al.: The epidermal growth factor receptor HER2 is not a major therapeutic target in Ewing sarcoma. J Pediatr Hematol Oncol 2003, 25:459–466.

    Article  PubMed  Google Scholar 

  37. Guan H, Jia SF, Zhou Z, et al.: Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing’s sarcoma cells in vitro and in vivo. Clin Cancer Res 2005, 11:2008–2017.

    Article  PubMed  CAS  Google Scholar 

  38. Franklin MC, Carey KD, Vajdos FF, et al.: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004, 5:317–328.

    Article  PubMed  CAS  Google Scholar 

  39. Agus DB, Akita RW, Fox WD, et al.: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002, 2:127–137.

    Article  PubMed  CAS  Google Scholar 

  40. Schindler T, Bornmann W, Pellicena P, et al.: Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000, 289:1938–1942.

    Article  PubMed  CAS  Google Scholar 

  41. Heinrich MC, Griffith DJ, Druker BJ, et al.: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000, 96:925–932.

    PubMed  CAS  Google Scholar 

  42. Product information:Gleevec, imatinib mesylate. East Hanover, NJ:Novartis Pharmaceuticals; 2002.

  43. Druker BJ, Tamura S, Buchdunger E, et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561–566.

    Article  PubMed  CAS  Google Scholar 

  44. McArthur GA, Demetri GD, van Oosterom A, et al.: Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib:Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005, 23:866–873.

    Article  PubMed  CAS  Google Scholar 

  45. Verweij J, van Oosterom A, Blay JY, et al.: Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003, 39:2006–2011.

    Article  PubMed  CAS  Google Scholar 

  46. Debiec-Rychter M, Cools J, Dumez H, et al.: Mechanisms of resistance to imatinib mesylate in gastro-intestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005, 128:270–279.

    Article  PubMed  CAS  Google Scholar 

  47. Demetri GD:Phase III, multicenter, randomized, doubleblind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST. Paper presented at the 2005 ASCO Annual Meeting. Orlando, FL; May 13–17, 2005.

  48. Steinert DM, Patel SR: Recent studies in novel therapy for metastatic sarcomas. Hematol Oncol Clin North Am 2005, 19:573–590.

    Article  PubMed  Google Scholar 

  49. Gleave ME, Monia BP: Antisense therapy for cancer. Nat Rev Cancer 2005, 5:468–479.

    Article  PubMed  CAS  Google Scholar 

  50. Morris MJ, Tong WP, Cordon-Cardo C, et al.: Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2002, 8:679–683.

    PubMed  CAS  Google Scholar 

  51. Tolcher AW, Kuhn J, Schwartz G, et al.: A phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2004, 10:5048–5057.

    Article  PubMed  CAS  Google Scholar 

  52. Rudin CM, Kozloff M, Hoffman PC, et al.: Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 2004, 22:1110–1117.

    Article  PubMed  CAS  Google Scholar 

  53. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al.: Bevacizumab in combination with fluorouracil and leucovorin:an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005, 23:3502–3508.

    Article  PubMed  CAS  Google Scholar 

  54. Zondor SD, Medina PJ: Bevacizumab:an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 2004, 38:1258–1264.

    Article  PubMed  CAS  Google Scholar 

  55. Product information:Avastin. San Francisco, CA:Genentech; 2004.

  56. Cobleigh MA, Langmuir VK, Sledge GW, et al.: A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003, 30:117–124.

    Article  PubMed  CAS  Google Scholar 

  57. Simpson GR, Mangham C, Cullinane C, et al.: MVD predicts disease-free and overall survival in tumours of the Ewing’s sarcoma family (ESFT). Br J Cancer 2002, 86:S95.

    Google Scholar 

  58. Dalal S, Berry AM, Cullinane CJ, et al.: Vascular endothelial growth factor:a therapeutic target for tumors of the Ewing’s sarcoma family. Clin Cancer Res 2005, 11:2364–2378.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, and Pharmacology and Therapeutics, Roswell Park Cancer Institute, 14263, Buffalo, NY, USA

    Michael K. K. Wong PhD, FRCPC (MD)

Authors
  1. Vinod Ravi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael K. K. Wong PhD, FRCPC
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ravi, V., Wong, M.K.K. Strategies and methodologies for identifying molecular targets in sarcomas and other tumors. Curr. Treat. Options in Oncol. 6, 487–497 (2005). https://doi.org/10.1007/s11864-005-0027-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-005-0027-9

Keywords

Search

Navigation